Skip to main content
Bazetta Blacklock-Schuver on Muck Rack

Bazetta Blacklock-Schuver

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bazetta

Contact Bazetta, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

|
By Andre Goy, Jeremy J. Rose, Steven Rosenberg, Steven Feldman, Jennifer N. Brudno, Robert P. T. Somerville, Victoria Shi, David C. Halverson, Juan C. Gea-Banacloche, Steven Z. Pavletic, Dennis D. Hickstein, Tangying L. Lu, Alexander T. Iwamoto, Roger Kurlander, Irina Maric, Brenna G. Hansen, Jennifer S. Wilder, Bazetta Blacklock-Schuver, Frances T. Hakim, Ronald E. Gress, Daniel Fowler
| ascopubs.org
Purpose Progressive malignancy is the leading cause of death after allogeneic hematopoietic stem-cell transplantation (alloHSCT). After alloHSCT, B-cell malignancies often are treated with unmanipulated donor lymphocyte infusions (DLIs) from the transplant donor. DLIs frequently are not effective at eradicating malignancy and often cause graft-versus-host disease, a potentially lethal immune response against normal recipient tissues.
Open in Who Shared Issue with article?
See all 1 articles